Overcoming Hypoxia-Restrained Radiotherapy Using an Erythrocyte-Inspired and Glucose-Activatable Platform.

Area of Science:

• Biomedical Engineering
• Cancer Research
• Drug Delivery Systems

Background:

• Tumor hypoxia significantly limits the efficacy of radiotherapy (RT), a potent cancer treatment.
• Existing oxygen delivery systems provide insufficient oxygen for sustained or repeated RT.
• Developing strategies to overcome tumor hypoxia is critical for enhancing RT effectiveness.

Purpose of the Study:

• To develop a glucose-regulated drug release platform for sustained tumor normoxia and repeated radiotherapy.
• To investigate the potential of this platform in normalizing tumor vasculature and reversing hypoxia.
• To evaluate the overall cancer treatment output of this novel approach.

Main Methods:

• Development of an erythrocyte-inspired, glucose-activatable drug release platform (Endo@GOx-ER).
• Administration of the platform to create a long-term normoxic tumor microenvironment.
• Repeated cycles of radiotherapy enabled by the sustained oxygen supply.
• Monitoring of Endostar plasma levels and tumor vasculature normalization.

Main Results:

• The platform achieved long-term tumor normoxia, allowing for repeated radiotherapy.
• Repeated administration led to sustained Endostar plasma levels, normalizing tumor vasculature.
• Chronic reversal of tumor hypoxia was observed.
• The Endo@GOx-ER enabled RT demonstrated significant cancer treatment efficacy.

Conclusions:

• This study presents the first strategy to overcome RT limitations caused by tumor hypoxia through vasculature normalization.
• The glucose-activatable, erythrocyte-inspired platform provides a long-term solution for repeated RT.
• The approach shows promising potential for clinical development in cancer therapy.